AI
PCVX icon

Atria Investments’s Vaxcyte PCVX Stock Holding History

Atria Investments’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,816
Closed -$222K – 2122
2025
Q2 		$222K Buy
6,816
+683
+11% +$22.4K ﹤0.01% 1866
2025
Q1 		$232K Buy
6,133
+3,637
+146% +$291K ﹤0.01% 1752
2024
Q4 		$204K Sell
2,496
-11
-0.4% -$1.09K ﹤0.01% 1775
2024
Q3 		$286K Buy
+2,507
New +$226K ﹤0.01% 1638

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Atria Investments's PCVX Position: Q3 2025 in Review

Atria Investments sold out of Vaxcyte (PCVX) in Q3 2025, closing a stake of 6,816 shares — an estimated $222K sold.

Atria Investments first reported a position in PCVX in Q3 2024 and held it in 4 quarters. The position peaked at $286K in Q3 2024. 285 funds tracked by Wall St. Rank hold PCVX as of Q3 2025.

  • Atria Investments reported no remaining Vaxcyte position as of Q3 2025 after selling out during the quarter.
  • Atria Investments sold 6,816 Vaxcyte shares in Q3 2025, an estimated $222K.
  • Atria Investments first reported a position in Vaxcyte in Q3 2024 and held it in 4 quarters.
  • Atria Investments's Vaxcyte position peaked at $286K in Q3 2024.
  • 285 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2025.

Based on Atria Investments's 13F filing for Q3 2025, filed 6 Nov 2025.